Related Experiment Video
Updated: Jul 3, 2026
08:27
Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
[Efficacy of adalimumab].
1Servicio Dermatología. Hospital La Paz. Universidad Autónoma de Madrid. España. mcasado.hulp@salud.madrid.org
Actas Dermo-Sifiliograficas
|August 19, 2008
Summary
This review examines adalimumab, a biologic treatment for psoriasis. It details its efficacy, usage guidelines, and clinical trial data, including CHAMPION and REVEAL studies.
Area of Science:
- Immunodermatology
- Pharmacology
Context:
- Psoriasis is a chronic inflammatory skin condition.
- Biologic therapies represent a significant advancement in psoriasis management.
Purpose:
- To review the efficacy and application of adalimumab in psoriasis treatment.
- To consolidate information on adalimumab's mechanism, indications, dosing, and clinical evidence.
Summary:
- Adalimumab is a biologic agent targeting tumor necrosis factor-alpha.
- This review covers therapeutic indications, dosing strategies, and guidelines for adalimumab in psoriasis.
- Key clinical trials, CHAMPION and REVEAL, demonstrating adalimumab's efficacy are discussed.
Impact:
- Provides a comprehensive overview for clinicians managing psoriasis with adalimumab.
- Highlights the importance of evidence-based treatment selection for psoriasis.
- Contributes to understanding the role of biologics in moderating immune responses in psoriasis.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:22Dose-Response Relationship: Potency and Efficacy
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...